PRS Global Open • 2019 ranging from 150 to 360 days). Two patients had lesions affecting the upper third of the face, and symmetry was achieved after unilateral treatment of the frontalis muscle. Three patients had injury in the middle third; their treatment depended of analysis of the deviation vectors when smiling and frowning, as to decide which muscle groups should be treated (vertical: upper lip lifter muscles; upper oblique: lifters of the angle of the mouth muscles; and horizontal: risorius muscle). Four patients were affected in the lower third (inferior deviation vectors) and were treated with 2 points to paralyze the lower lip depressor muscles. Correction of asymmetry was achieved in all cases. Recovery from the nerve injury and BTXA application occurred symmetrically in both sides of the face in the following months. All patients with early onset of BTXA therapy (<30 days) had complete recovery of facial symmetry with a single application, evidence of neuropraxis. Patients with lesions of the upper third, those with late onset of BTXA treatment (>30 days), and those with >1 affected nervous branch presented definitive lesion, with partial recovery or improvement, and needed BTXA treatment every 6 months.
CONCLUSION:
Most facial nerve injuries post-facelifts presented favorable evolution for spontaneous resolution, except in the upper third of the face and in case of late lesions. Symmetry was achieved in all cases with low doses of BTXA in the suggested protocol points, avoiding an unhappy asymmetric patient in the following months. 
INTRODUCTION AND AIMS:
The Earfold implant system, made from a nickel-titanium alloy, is deployed and bends auricular cartilage to address an underdeveloped antihelical fold. In 2018, Kang et al 1 (the device inventor) published a series of 403 patients treated with the Earfold device, showing acceptable safety outcomes. The aim of this study is to report the early results and technical tips from 2 UK plastic surgeons implementing the Earfold system into their esthetic practice.
MATERIALS AND METHODS:
A retrospective review of all patients who received Earfold implants between February 2017 and August 2018 was undertaken. This was a consecutive series carried out in 2 separate UK clinics. Demographics, clinical outcomes, complications, and followup data were collected from electronic records.
KEY RESULTS:
A total of 79 implants were used in 36 patients, with 82% (n = 31) placed bilaterally. Mean age was 35 years (56% female). Overall complication rate leading to implant removal was 22% (n = 8), compared to 10% reported by Kang et al. 1 Indication for implant removal included implant visibility (n = 2), chronic pain (n = 2), undercorrection (n = 1), and erosion (n = 3). Three patients who had implants removed previously had an otoplasty procedure, and 1 was a recent ex-smoker. Eightyeight percent (7/8) of complications occurred in the first 50% of Earfold cases performed. Average follow-up time from surgery was 19 weeks.
CONCLUSIONS:
The Earfold system gives reproducible results that can be visualized by patients before surgery and is becoming increasingly popular. Our results indicate higher revision rates than those reported by Kang et al 1 but similar to their initial published results in 2016. 2 The trend seems to support a learning curve associated with Earfold, and we advise careful patient selection, in particular a history of previous otoplasty, when starting to use the device.
